Literature DB >> 23019418

MiR-9, -31, and -182 deregulation promote proliferation and tumor cell survival in colon cancer.

Lina Cekaite1, Juha K Rantala, Jarle Bruun, Marianne Guriby, Trude H Agesen, Stine A Danielsen, Guro E Lind, Arild Nesbakken, Olli Kallioniemi, Ragnhild A Lothe, Rolf I Skotheim.   

Abstract

Several microRNAs (miRNAs) are known to be deregulated in colon cancer, but the mechanisms behind their potential involvement on proliferation and tumor cell survival are unclear. The present study aimed to identify miRNAs with functional implications for development of colon cancer. The cell proliferation and apoptosis were examined following perturbations of miRNA levels by employing a comprehensive miRNA library screen. miRNAs nominated for relevance to colon cancer were validated on expression and functional levels. By integrating the effect of miRNA up-regulation with the endogenous miRNA expression levels within the HT29, HCT116, and SW480 colon cancer cell lines, we identified miRNAs controlling cell proliferation (n = 53) and apoptosis (n = 93). From these functionally nominated miRNAs, we narrowed the list to 10 oncogene- and 20 tumor suppressor-like miRNAs that were also differentially expressed between colon cancer (n = 80) and normal colonic mucosa (n = 20). The differential expressions of miR-9, miR-31, and miR-182 were successfully validated in a series of colon carcinomas (n = 30) and polyps (n = 10) versus normal colonic mucosa (n = 10), whereas the functional effect was confirmed in an in-depth validation using different cell viability and apoptotic markers. Several transcription factors and genes regulating cell proliferation were identified as putative target genes by integrative miRNA/mRNA expression analysis obtained from the same colon cancer patient samples. This study suggests that deregulated expression of miR-9, miR-31, and miR-182 during carcinogenesis plays a significant role in the development of colon cancer by promoting proliferation and tumor cell survival.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23019418      PMCID: PMC3459282          DOI: 10.1593/neo.121094

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  43 in total

1.  Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers.

Authors:  Chad J Creighton; Michael D Fountain; Zhifeng Yu; Ankur K Nagaraja; Huifeng Zhu; Mahjabeen Khan; Emuejevoke Olokpa; Azam Zariff; Preethi H Gunaratne; Martin M Matzuk; Matthew L Anderson
Journal:  Cancer Res       Date:  2010-02-23       Impact factor: 12.701

2.  The colorectal microRNAome.

Authors:  Jordan M Cummins; Yiping He; Rebecca J Leary; Ray Pagliarini; Luis A Diaz; Tobias Sjoblom; Omer Barad; Zvi Bentwich; Anna E Szafranska; Emmanuel Labourier; Christopher K Raymond; Brian S Roberts; Hartmut Juhl; Kenneth W Kinzler; Bert Vogelstein; Victor E Velculescu
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-27       Impact factor: 11.205

Review 3.  miRNAs as molecular biomarkers of cancer.

Authors:  Muller Fabbri
Journal:  Expert Rev Mol Diagn       Date:  2010-05       Impact factor: 5.225

4.  DNA sequence profiles of the colorectal cancer critical gene set KRAS-BRAF-PIK3CA-PTEN-TP53 related to age at disease onset.

Authors:  Marianne Berg; Stine A Danielsen; Terje Ahlquist; Marianne A Merok; Trude H Ågesen; Morten H Vatn; Tom Mala; Ole H Sjo; Arne Bakka; Ingvild Moberg; Torunn Fetveit; Øystein Mathisen; Anders Husby; Oddvar Sandvik; Arild Nesbakken; Espen Thiis-Evensen; Ragnhild A Lothe
Journal:  PLoS One       Date:  2010-11-12       Impact factor: 3.240

5.  Suppression of microRNA-31 increases sensitivity to 5-FU at an early stage, and affects cell migration and invasion in HCT-116 colon cancer cells.

Authors:  Chao-Jie Wang; Johannes Stratmann; Zong-Guang Zhou; Xiao-Feng Sun
Journal:  BMC Cancer       Date:  2010-11-09       Impact factor: 4.430

6.  MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma.

Authors:  Aaron J Schetter; Suet Yi Leung; Jane J Sohn; Krista A Zanetti; Elise D Bowman; Nozomu Yanaihara; Siu Tsan Yuen; Tsun Leung Chan; Dora L W Kwong; Gordon K H Au; Chang-Gong Liu; George A Calin; Carlo M Croce; Curtis C Harris
Journal:  JAMA       Date:  2008-01-30       Impact factor: 56.272

Review 7.  Colorectal cancer.

Authors:  R Midgley; D Kerr
Journal:  Lancet       Date:  1999-01-30       Impact factor: 79.321

8.  Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer.

Authors:  O Slaby; M Svoboda; P Fabian; T Smerdova; D Knoflickova; M Bednarikova; R Nenutil; R Vyzula
Journal:  Oncology       Date:  2008-01-15       Impact factor: 2.935

9.  A cell spot microarray method for production of high density siRNA transfection microarrays.

Authors:  Juha K Rantala; Rami Mäkelä; Anna-Riina Aaltola; Petra Laasola; John-Patrick Mpindi; Matthias Nees; Petri Saviranta; Olli Kallioniemi
Journal:  BMC Genomics       Date:  2011-03-28       Impact factor: 3.969

10.  Down-regulated miR-9 and miR-433 in human gastric carcinoma.

Authors:  Hongchun Luo; Hongbin Zhang; Zhenzhen Zhang; Xia Zhang; Bo Ning; Jinjun Guo; Na Nie; Bo Liu; Xiaoling Wu
Journal:  J Exp Clin Cancer Res       Date:  2009-06-16
View more
  71 in total

Review 1.  The impact of the Cancer Genome Atlas on lung cancer.

Authors:  Jeremy T-H Chang; Yee Ming Lee; R Stephanie Huang
Journal:  Transl Res       Date:  2015-08-10       Impact factor: 7.012

Review 2.  Causes and consequences of nuclear envelope alterations in tumour progression.

Authors:  Emily S Bell; Jan Lammerding
Journal:  Eur J Cell Biol       Date:  2016-06-25       Impact factor: 4.492

Review 3.  MicroRNAs in colorectal cancer as markers and targets: Recent advances.

Authors:  Jing-Jia Ye; Jiang Cao
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

4.  Cancer subclonal genetic architecture as a key to personalized medicine.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2013-12       Impact factor: 5.715

5.  MicroRNA-9 promotes tumorigenesis and mediates sensitivity to cisplatin in primary epithelial ovarian cancer cells.

Authors:  Hong-Min Zhao; Wei Wei; Yu-Hui Sun; Jian-Hua Gao; Qi Wang; Jian-Hua Zheng
Journal:  Tumour Biol       Date:  2015-04-07

6.  Up-regulation of miR-9 expression as a poor prognostic biomarker in patients with non-small cell lung cancer.

Authors:  T Xu; X Liu; L Han; H Shen; L Liu; Y Shu
Journal:  Clin Transl Oncol       Date:  2013-09-10       Impact factor: 3.405

7.  MicroRNA-31 contributes to colorectal cancer development by targeting factor inhibiting HIF-1α (FIH-1).

Authors:  Tao Chen; Li-Qing Yao; Qiang Shi; Zhong Ren; Le-Chi Ye; Jian-Min Xu; Ping-Hong Zhou; Yun-Shi Zhong
Journal:  Cancer Biol Ther       Date:  2014-02-12       Impact factor: 4.742

8.  A miRNA-binding site single nucleotide polymorphism in the 3'-UTR region of the NOD2 gene is associated with colorectal cancer.

Authors:  Fatemeh Ahangari; Rasoul Salehi; Mansour Salehi; Hosein Khanahmad
Journal:  Med Oncol       Date:  2014-08-23       Impact factor: 3.064

Review 9.  Function and regulation of microRNA-31 in development and disease.

Authors:  Nadezda A Stepicheva; Jia L Song
Journal:  Mol Reprod Dev       Date:  2016-08-02       Impact factor: 2.609

10.  Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer.

Authors:  Yuji Toiyama; Masanobu Takahashi; Keun Hur; Takeshi Nagasaka; Koji Tanaka; Yasuhiro Inoue; Masato Kusunoki; C Richard Boland; Ajay Goel
Journal:  J Natl Cancer Inst       Date:  2013-05-23       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.